New study suggests BRCA1 breast cells undergo changes before becoming cancerous
News
NICE rejects AZ’s Lynparza for metastatic prostate cancer
Appraisal committee highlighted uncertainties in the clinical evidence for PARP inhibitor
Parkinson’s UK invests £1.2m in drug design project
One-year project aims to refine molecule for potential drug development
SMC accepts Zolgensma and Rozlytrek for use by NHS Scotland
Both medicines reviewed through the SMC’s PACE process
INTCR 2021 invites the best and brightest from all corners of the globe to enter
The PharmaTimes International Clinical Researcher of the Year is calling on the most talented clinical researchers to try their hand and reap the rewards in the 2021 competition.
Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy
Data from two Phase III studies demonstrated durable viral suppression in HIV-1 patients
CHMP issues positive opinion for Lilly’s COVID-19 antibodies
Advice recommends the use of bamlanivimab alone and combined with etesevimab to treat COVID-19
Radiotherapy responses may be improved with targeted immunotherapy, study suggests
Researchers studied inflammation in bowel tumour samples taken before and after radiotherapy
NHS England agrees deal with Novartis for access to SMA gene therapy Zolgensma
NHS England has secured drug for use at a ‘substantial’ confidential discount
FDA to review Sanofi/Regeneron’s Dupixent in children with uncontrolled asthma
Sanofi is also planning an EU regulatory submission for Dupixent in the same indication
ClinSpec Diagnostics reaches funding target of £3.5m
University of Strathclyde spin-out is developing liquid biopsies for early cancer detection
Lilly’s tirzepatide claims head-to-head trial win against injectable semaglutide
Tirzepatide demonstrated superior A1C and body weight reduction in type 2 diabetes
Modified COVID-19 vaccines can avoid ‘lengthy’ clinical studies, says MHRA
UK’s regulatory authority will fast-track jabs modified to new variants
ConserV Bio partners with eTheRNA on mRNA vaccine development
Collaboration will focus on vaccines for infectious diseases
NICE rejects rare blood cancer treatment Poteligeo in final appraisal
Final appraisal document said that clinical trial evidence for Poteligeo is ‘very uncertain’
